On this page

DIANEAL LOW CALCIUM WITH DEXTROSE

sodium chloride, sodium lactate, calcium chloride, magnesium chloride and dextrose · Injection, Solution

Prescription NDA TE AT RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
DIANEAL LOW CALCIUM WITH DEXTROSE
Generic name
sodium chloride, sodium lactate, calcium chloride, magnesium chloride and dextrose
Dosage form
Injection, Solution
Route
Intraperitoneal
Marketing category
—
Labeler
Vantive US Healthcare LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
11
NDC product codes
26
Packages
41
Data completeness
84% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Calcium Chloride 18.3 mg/100mL 828525 View
Calcium Chloride 18.4 mg/100mL 828525 View
Dextrose Monohydrate 1.36 g/100mL 799999 View
Dextrose Monohydrate 1.5 g/100mL 799999 View
Dextrose Monohydrate 2.27 g/100mL 799999 View
Dextrose Monohydrate 2.5 g/100mL 799999 View
Dextrose Monohydrate 4.25 g/100mL 799999 View
Magnesium Chloride 5.08 mg/100mL 799999 View
Magnesium Chloride 5.1 mg/100mL 799999 View
Sodium Chloride 538 mg/100mL 707251 View
Sodium Lactate 448 mg/100mL 799999 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Injection, Solution
Route of administration
Intraperitoneal
Presentations
67

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Acidifying Activity [MoA] MoA All 14 members
Blood Coagulation Factor [EPC] EPC All 23 members
Calcium [CS] CS All 23 members
Calculi Dissolution Agent [EPC] EPC All 33 members
Cations EPC All 23 members
Divalent [CS] CS All 23 members
Increased Coagulation Factor Activity [PE] PE All 23 members
Increased Large Intestinal Motility [PE] PE All 83 members
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE] PE All 83 members
Inhibition Small Intestine Fluid/Electrolyte Absorption [PE] PE All 30 members
Magnesium Ion Exchange Activity [MoA] MoA All 30 members
Osmotic Activity [MoA] MoA All 105 members
Osmotic Laxative [EPC] EPC All 103 members
Phosphate Binder [EPC] EPC All 42 members
Phosphate Chelating Activity [MoA] MoA All 42 members
Stimulation Large Intestine Fluid/Electrolyte Secretion [PE] PE All 53 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
017512
Application type
NDA · New Drug Application
Approval date
September 27, 1978
Sponsor
VANTIVE US HLTHCARE
Products on application
15
Submissions recorded
102
Products approved under application 017512.
Product Trade name Form Strength Ingredient Status TE Flags
017512-001 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Discontinued —
017512-002 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Discontinued —
017512-003 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Discontinued —
017512-004 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Prescription AT RLD
017512-005 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Prescription AT RLD
017512-006 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Prescription AT RLD
017512-007 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Discontinued —
017512-008 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Discontinued —
017512-009 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Discontinued —
017512-010 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Discontinued —
017512-011 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Discontinued — RLD
017512-012 DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Prescription AT RLD
017512-013 DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Prescription AT RLD
017512-014 DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Prescription AT RLD
017512-015 DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER SOLUTION CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE Prescription AT RLD

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
Yes
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 017512.
Type No. Action Status Date Review
Supplement 143 Manufacturing (CMC) Approved April 16, 2026 N/A
Supplement 125 Manufacturing (CMC) Approved December 9, 2016 Standard
Supplement 123 Labeling Approved August 16, 2016 Standard
Supplement 124 Manufacturing (CMC) Approved August 1, 2016 Standard
Supplement 122 Labeling Approved September 1, 2015 Standard
Supplement 121 Manufacturing (CMC) Approved July 29, 2015 Standard
Supplement 120 Manufacturing (CMC) Approved July 29, 2015 Standard
Supplement 119 Manufacturing (CMC) Approved May 22, 2015 Standard
Supplement 118 Labeling Approved February 9, 2015 Standard
Supplement 117 Manufacturing (CMC) Approved September 30, 2014 Standard
Supplement 116 Manufacturing (CMC) Approved April 26, 2013 Standard
Supplement 113 Labeling Approved April 19, 2013 Standard
Supplement 108 Manufacturing (CMC) Approved December 19, 2008 N/A
Supplement 106 Labeling Approved August 9, 2005 Standard
Supplement 104 Labeling Approved August 9, 2005 Standard
Supplement 99 Manufacturing (CMC) Approved September 20, 2002 Standard
Supplement 98 Manufacturing (CMC) Approved August 22, 2001 Standard
Supplement 97 Manufacturing (CMC) Approved September 20, 2000 Standard
Supplement 96 Manufacturing (CMC) Approved April 29, 1997 Standard
Supplement 95 Manufacturing (CMC) Approved January 17, 1997 Standard
Supplement 94 Manufacturing (CMC) Approved July 2, 1996 Standard
Supplement 89 Manufacturing (CMC) Approved July 21, 1995 Standard
Supplement 92 Manufacturing (CMC) Approved September 30, 1994 Standard
Supplement 91 Manufacturing (CMC) Approved July 1, 1994 Standard
Supplement 93 Manufacturing (CMC) Approved February 18, 1994 Standard
Supplement 85 Manufacturing (CMC) Approved June 14, 1993 Standard
Supplement 88 Manufacturing (CMC) Approved November 23, 1992 Standard
Supplement 84 Manufacturing (CMC) Approved June 12, 1992 Standard
Supplement 86 Manufacturing (CMC) Approved April 29, 1991 Standard
Supplement 82 Manufacturing (CMC) Approved February 15, 1991 Standard
Supplement 83 Labeling Approved November 28, 1990 —
Supplement 81 Labeling Approved July 11, 1990 —
Supplement 80 Manufacturing (CMC) Approved July 11, 1990 Standard
Supplement 73 Labeling Approved October 16, 1989 —
Supplement 72 Manufacturing (CMC) Approved October 16, 1989 Standard
Supplement 79 Manufacturing (CMC) Approved July 26, 1989 Standard
Supplement 78 Manufacturing (CMC) Approved January 12, 1989 Standard
Supplement 77 Labeling Approved January 10, 1989 —
Supplement 76 Manufacturing (CMC) Approved January 10, 1989 Standard
Supplement 75 Manufacturing (CMC) Approved July 25, 1987 Standard
Supplement 71 Manufacturing (CMC) Approved May 28, 1987 Standard
Supplement 74 Manufacturing (CMC) Approved January 14, 1987 Standard
Supplement 69 Manufacturing (CMC) Approved September 4, 1986 Standard
Supplement 70 Manufacturing (CMC) Approved May 27, 1986 Standard
Supplement 66 Manufacturing (CMC) Approved February 27, 1986 Standard
Supplement 68 Labeling Approved November 18, 1985 —
Supplement 67 Manufacturing (CMC) Approved November 18, 1985 Standard
Supplement 62 Labeling Approved August 29, 1985 —
Supplement 61 Labeling Approved August 29, 1985 —
Supplement 46 Manufacturing (CMC) Approved August 28, 1985 Standard
Supplement 45 Manufacturing (CMC) Approved August 28, 1985 Standard
Supplement 64 Labeling Approved July 16, 1985 —
Supplement 63 Manufacturing (CMC) Approved July 16, 1985 Standard
Supplement 18 Labeling Approved July 16, 1985 —
Supplement 17 Manufacturing (CMC) Approved July 16, 1985 Standard
Supplement 55 Manufacturing (CMC) Approved June 13, 1985 Standard
Supplement 65 Manufacturing (CMC) Approved April 15, 1985 Standard
Supplement 58 Labeling Approved April 10, 1985 —
Supplement 43 Manufacturing (CMC) Approved January 24, 1985 Standard
Supplement 54 Manufacturing (CMC) Approved September 22, 1984 Standard

Review documents

  • 0 · Supplement · August 24, 2026
  • 0 · Supplement · August 24, 2026
  • 0 · Supplement · August 16, 2016
  • 0 · Supplement · August 16, 2016
  • 0 · Supplement · August 16, 2016
  • 0 · Supplement · August 16, 2016
  • 0 · Supplement · August 16, 2016
  • 0 · Supplement · August 16, 2016
  • 0 · Supplement · September 4, 2015
  • 0 · Supplement · September 4, 2015
  • 0 · Supplement · July 31, 2015
  • 0 · Supplement · July 31, 2015
  • 0 · Supplement · July 30, 2015
  • 0 · Supplement · July 30, 2015
  • 0 · Supplement · February 10, 2015
  • 0 · Supplement · February 10, 2015
  • 0 · Supplement · April 24, 2013
  • 0 · Supplement · April 23, 2013
  • 0 · Supplement · January 2, 2009
  • 0 · Supplement · December 24, 2008
  • 0 · Supplement · August 11, 2005
  • 0 · Supplement · August 11, 2005

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260416). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260416

Indications and Usage

openFDA Drug Labeling

1 INDICATIONS AND USAGE DIANEAL peritoneal dialysis solutions are indicated for patients in acute or chronic renal failure. For management of acute or chronic renal failure.

Dosage and Administration

openFDA Drug Labeling

2 DOSAGE AND ADMINISTRATION For intraperitoneal administration only. ( 2 ) 2.1 Basic Dosing Information DIANEAL peritoneal dialysis solutions are intended for intraperitoneal administration only. Not for intravenous or intra-arterial administration. Select mode of therapy, frequency of treatment, formulation, fill volume, duration of dwell, and length of dialysis based on the patient’s clinical condition, fluid, electrolyte and specific needs. The fill volume depends on body size, usually from 2.0 to 2.5 liters per 1.73m 2 for adults. DIANEAL peritoneal dialysis solutions are intended for use in Continuous Ambulatory Peritoneal Dialysis (CAPD) or Automated Peritoneal Dialysis (APD). Refer to directions accompanying ancillary equipment for CAPD and APD system preparation. Product Selection To avoid the risk of severe dehydration and hypovolemia and to minimize the loss of protein, it is advisable to select the peritoneal dialysis solution with the lowest level of osmolarity consistent with the fluid removal requirements for that exchange. As the patient’s body weight becomes closer to the ideal dry weight, lowering the dextrose concentration of DIANEAL solution is recommended. DIANEAL 4.25% dextrose-containing solution has the highest osmolarity of the DIANEAL solutions and using it for all exchanges may cause dehydration [see Dosage Forms and Strengths (3) ] . 2.2 Adding Medications If the resealable rubber plug on the medication port is missing or partly removed, do not use the product if medication is to be added. To add a medication: 1. Put on mask. Clean and/or disinfect hands. 2. Prepare medication port site using aseptic technique. 3. Using a syringe with a 1-inch long, 25- to 19-gauge needle, puncture the medication port and inject additive. 4. Reposition container with container ports up and evacuate medication port by squeezing and tapping it. 5. Mix solution and additive thoroughly. 2.3 Directions for Use Warming DIANEAL peritoneal dialysis solution can be warmed to 37°C (98.6°F). Only dry heat should be used. For CAPD, it is best to warm solutions within the overwrap using a heating pad. Do not immerse DIANEAL solutions in water for warming. Do not use a microwave oven to warm DIANEAL solutions. To Open To open, tear the overwrap down at the slit and remove the solution container. Do not use sharp objects to remove the overwrap. Product Inspection Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use solutions that are cloudy, discolored, contain visible particulate matter, or show evidence of leakage. Some opacity of the plastic, due to moisture absorption during the sterilization process, may be observed. This does not affect the solution quality or safety and may often leave a slight amount of moisture within the overwrap. The opacity should diminish gradually. Inspect the bag connector to ensure the tip protector (pull ring or blue pull tip) is attached. Do not use if the tip protector is not attached to the connector. Inspect the DIANEAL solution container for signs of leakage and check for minute leaks by squeezing the container firmly. If the container has frangible(s), inspect that they are positioned correctly and are not broken. Do not use DIANEAL solution if the frangible(s) are broken or leaks are suspected as sterility may be impaired. For DIANEAL solutions in ULTRABAG containers, inspect the tubing and drain container for presence of solution. Small droplets are acceptable, but if solution flows past the frangible prior to use, do not use and discard the units. CAPD therapy using ULTRABAG containers Select appropriate formulation from Table 1. Put on mask. Clean and/or disinfect hands. Using aseptic technique; 1. Uncoil tubing and drain bag, ensuring that the transfer set is closed. 2. Break the connector (Y-set) frangible. 3. Remove the tip protector from connector of solution container. Do not reuse the solution or container …

Dosage Forms and Strengths

openFDA Drug Labeling

3 DOSAGE FORMS AND STRENGTHS DIANEAL peritoneal dialysis solution is clear with color being slightly yellow to colorless and is formulated with the following ionic concentrations: Table 1 - DIANEAL PD-2 and Low Calcium Peritoneal Dialysis Solution ULTRABAG Container for CAPD therapy AMBU-FLEX Container with pull ring for APD therapy Ionic Concentration (mEq/L) OSMOLARITY (mOsmol/L) (calc) pH Sodium Calcium Magnesium Chloride Lactate DIANEAL PD-2 1.5% Dextrose 346 5.2 (4.0 to 6.5) 132 3.5 0.5 96 40 DIANEAL PD-2 2.5% Dextrose 396 5.2 (4.0 to 6.5) 132 3.5 0.5 96 40 DIANEAL PD-2 4.25% Dextrose 485 5.2 (4.0 to 6.5) 132 3.5 0.5 96 40 DIANEAL Low Calcium (2.5 mEq/L) 1.5% Dextrose 344 5.2 (4.0 to 6.5) 132 2.5 0.5 95 40 DIANEAL Low Calcium (2.5 mEq/L) 2.5% Dextrose 395 5.2 (4.0 to 6.5) 132 2.5 0.5 95 40 DIANEAL Low Calcium (2.5 mEq/L) 4.25% Dextrose 483 5.2 (4.0 to 6.5) 132 2.5 0.5 95 40 Table 2 - DIANEAL Low Calcium Peritoneal Dialysis Solution Plastic container with blue pull tip for APD therapy Ionic Concentration (mEq/L) OSMOLARITY (mOsmol/L) (calc) pH Sodium Calcium Magnesium Chloride Lactate DIANEAL Low Calcium (2.5 mEq/L) 1.5% Dextrose 344 5.0 to 6.5 132 2.5 0.5 95 40 DIANEAL Low Calcium (2.5 mEq/L) 2.5% Dextrose 395 5.0 to 6.5 132 2.5 0.5 95 40 DIANEAL Low Calcium (2.5 mEq/L) 4.25% Dextrose 483 5.0 to 6.5 132 2.5 0.5 95 40 Table 3 – DIANEAL PD-2 and DIANEAL Low Calcium Peritoneal Dialysis Solution Plastic container with pull ring for APD therapy OSMOLARITY (mOsmol/L) (calc) pH Ionic Concentration (mEq/L) Sodium Calcium Magnesium Chloride Lactate DIANEAL PD-2 1.5% Dextrose 346 5.0 to 5.6 132 3.5 0.5 96 40 DIANEAL PD-2 2.5% Dextrose 396 5.0 to 5.6 132 3.5 0.5 96 40 DIANEAL PD-2 4.25% Dextrose 485 5.0 to 5.6 132 3.5 0.5 96 40 DIANEAL Low Calcium (2.5 mEq/L) 1.5% Dextrose 344 5.0 to 5.6 132 2.5 0.5 95 40 DIANEAL Low Calcium (2.5 mEq/L) 2.5% Dextrose 395 5.0 to 5.6 132 2.5 0.5 95 40 DIANEAL Low Calcium (2.5 mEq/L) 4.25% Dextrose 483 5.0 to 5.6 132 2.5 0.5 95 40 DIANEAL solutions are available in multiple combinations of ingredients and in composition, calculated osmolarity, pH, and ionic concentrations. See full prescribing information for detailed descriptions of each formulation. ( 3 )

Contraindications

openFDA Drug Labeling

4 CONTRAINDICATIONS DIANEAL peritoneal dialysis solutions are contraindicated in patients with severe lactic acidosis. • Pre-existing severe lactic acidosis ( 4 )

Warnings and Cautions

openFDA Drug Labeling

5 WARNINGS AND PRECAUTIONS • Encapsulating peritoneal sclerosis ( 5.1 ) • Peritonitis: Initiate appropriate antimicrobial therapy ( 5.1 ) • Monitor for lactic acidosis in patients at risk ( 5.2 ) • Monitor for electrolyte, fluid, and nutrition imbalances ( 5.4 ) 5.1 Peritonitis and Encapsulating Peritoneal Sclerosis Peritonitis has been associated with DIANEAL peritoneal dialysis solution use. Following use, inspect the drained fluid for the presence of fibrin or cloudiness, which may indicate the presence of peritonitis. Improper clamping or priming sequence may result in infusion of air into the peritoneal cavity, which may result in abdominal pain and/or peritonitis. If peritonitis occurs, treat with appropriate therapy. Encapsulating Peritoneal Sclerosis (EPS), sometimes fatal, is a complication of peritoneal dialysis therapy and has been reported in patients using DIANEAL solutions. 5.2 Lactic Acidosis Monitor patients with conditions known to increase the risk of lactic acidosis [e.g., severe hypotension or sepsis that can be associated with acute renal failure, hepatic failure, inborn errors of metabolism, and treatment with drugs such as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)] before the start of treatment and during treatment with lactate-based peritoneal dialysis solutions. Use of DIANEAL solutions in patients with severe lactic acidosis is contraindicated [see Contraindications (4) ]. 5.3 Overinfusion Overinfusion of peritoneal dialysis solution volume into the peritoneal cavity may be characterized by abdominal distention, feeling of fullness and/or shortness of breath. Drain the peritoneal dialysis solution from the peritoneal cavity to treat overinfusion. 5.4 Electrolyte, Fluid, and Nutrition Imbalances Peritoneal dialysis may affect a patient’s protein, water-soluble vitamin, potassium, bicarbonate, calcium, and magnesium levels and volume status. Monitor hematology, electrolytes, blood chemistry and fluid status periodically and take appropriate clinical action. Potassium is omitted from DIANEAL solutions because dialysis may be performed to correct hyperkalemia. In situations where there is a normal serum potassium level or hypokalemia, addition of potassium chloride (up to a concentration of 4 mEq/L) to the solution may be necessary to prevent severe hypokalemia. Monitor fluid status to avoid hyper- or hypovolemia and potentially severe consequences including congestive heart failure, volume depletion and hypovolemic shock. 5.5 Hyperglycemia DIANEAL solutions contain dextrose and may increase the risk for hyperglycemia in patients with impaired glucose tolerance. Patients may require initiation or modification of antidiabetic therapy during treatment with DIANEAL solutions. Monitor blood glucose.

Adverse Reactions

openFDA Drug Labeling

6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the label: Peritonitis and Encapsulating Peritoneal Sclerosis [see Warnings and Precautions (5.1) ] Electrolyte and Fluid Imbalances [see Warnings and Precautions (5.4) ] To report SUSPECTED ADVERSE REACTIONS, contact Vantive US Healthcare LLC at 1-855-857-0003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience There are no data available on adverse reactions from controlled clinical trials conducted to evaluate the safety of DIANEAL peritoneal dialysis solutions. 6.2 Post-Marketing Experience The following adverse experiences have been identified during post-approval use of DIANEAL solutions or in conjunction with performing the peritoneal dialysis procedure. Because these experiences are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship during drug exposure. Most of these adverse experiences are believed to be consequences of peritoneal dialysis. INFECTIONS AND INFESTATIONS: Fungal peritonitis, Peritonitis bacterial, Catheter related infection METABOLISM AND NUTRITION DISORDERS: Hypovolemia, Hypervolemia, Fluid retention, Hypokalemia, Hyponatremia, Dehydration, Hypochloremia VASCULAR DISORDERS: Hypotension, Hypertension RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS: Dyspnea GASTROINTESTINAL DISORDERS: Sclerosing encapsulating peritonitis, Peritonitis, Peritoneal cloudy effluent, Vomiting, Diarrhea, Nausea, Constipation, Abdominal pain, Abdominal distension, Abdominal discomfort SKIN AND SUBCUTANEOUS DISORDERS: Stevens-Johnson syndrome, Urticaria, Rash, (including pruritic, erythematous and generalized), Pruritus MUSCULOSKELETAL, CONNECTIVE TISSUE DISORDERS: Myalgia, Muscle spasms, Musculoskeletal pain GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Generalized edema, Pyrexia, Malaise, Infusion site pain, Catheter related complication

Drug Interactions

openFDA Drug Labeling

7 DRUG INTERACTIONS As with other dialysis solutions, blood concentrations of dialyzable drugs may be reduced by dialysis. Dosage adjustment of concomitant medications may be necessary. Diabetic patients may require dosage adjustments of insulin or other treatments for hyperglycemia [see Warnings and Precautions (5.5) ] .

Use in Specific Populations

openFDA Drug Labeling

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy DIANEAL peritoneal dialysis solution is a pharmacologically inactive solution. While there are no adequate and well controlled studies in pregnant women, appropriate administration of DIANEAL solutions, with appropriate monitoring of hematology, electrolytes, blood chemistry and fluid status is not expected to cause fetal harm. Animal reproduction studies have not been conducted with DIANEAL solutions. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. 8.2 Lactation The components of DIANEAL solutions are excreted in human milk. 8.4 Pediatric Use Safety and effectiveness have been established based on published clinical data. No adequate and well-controlled studies have been conducted with DIANEAL solutions in pediatric patients. 8.5 Geriatric Use Safety and effectiveness have been established based on published clinical data.

Mechanism of Action

openFDA Drug Labeling

12.1 Mechanism of Action DIANEAL peritoneal dialysis solutions are a pharmacologically inactive, hypertonic peritoneal dialysis solution containing dextrose, a monosaccharide, as the primary osmotic agent. An osmotic gradient must be created between the peritoneal membrane and the dialysis solution in order for ultrafiltration to occur. The hypertonic concentration of glucose in DIANEAL solutions exert an osmotic pressure across the peritoneal membrane resulting in transcapillary ultrafiltration. Like other peritoneal dialysis solutions, DIANEAL solutions contain electrolytes to facilitate the correction of electrolyte abnormalities. DIANEAL solutions contain a buffer, lactate, to help normalize acid-base abnormalities.

Description

openFDA Drug Labeling

11 DESCRIPTION DIANEAL peritoneal dialysis solutions are sterile, nonpyrogenic solutions in flexible containers for intraperitoneal administration only. The peritoneal dialysis solutions contain no bacteriostatic or antimicrobial agents. DIANEAL solutions are hyperosmolar solutions. Table 4 - DIANEAL PD-2 and Low Calcium Peritoneal Dialysis Solution ULTRABAG Container for CAPD therapy AMBU-FLEX/Plastic Container with pull ring for APD therapy Composition/100 mL *Dextrose, Hydrous, USP Sodium Chloride, USP (NaCl) Sodium Lactate (C 3 H 5 NaO 3 ) Calcium Chloride, USP (CaCl2•2H2O) Magnesium Chloride, USP (MgCl2•6H2O) DIANEAL PD-2 1.5% Dextrose 1.5 g 538 mg 448 mg 25.7 mg 5.08 mg DIANEAL PD-2 2.5% Dextrose 2.5 g 538 mg 448 mg 25.7 mg 5.08 mg DIANEAL PD-2 4.25% Dextrose 4.25 g 538 mg 448 mg 25.7 mg 5.08 mg DIANEAL Low Calcium (2.5 mEq/L) 1.5% Dextrose 1.5 g 538 mg 448 mg 18.3 mg 5.08 mg DIANEAL Low Calcium (2.5 mEq/L) 2.5% Dextrose 2.5 g 538 mg 448 mg 18.3 mg 5.08 mg DIANEAL Low Calcium (2.5 mEq/L) 4.25% Dextrose 4.25 g 538 mg 448 mg 18.3 mg 5.08 mg Table 5 - DIANEAL Low Calcium Peritoneal Dialysis Solution Plastic container with blue pull tip for APD therapy Composition/100 mL *Dextrose, Hydrous Sodium Chloride (NaCl) Sodium Lactate (C3H5NaO3) Calcium Chloride (CaCl2•2H2O) Magnesium Chloride (MgCl2•6H2O) DIANEAL Low Calcium (2.5 mEq/L) 1.5% Dextrose 1.5 g 538 mg 448 mg 18.4 mg 5.08 mg DIANEAL Low Calcium (2.5 mEq/L) 2.5% Dextrose 2.5 g 538 mg 448 mg 18.4 mg 5.08 mg DIANEAL Low Calcium (2.5 mEq/L) 4.25% Dextrose 4.25 g 538 mg 448 mg 18.4 mg 5.08 mg The plastic container is fabricated from polyvinyl chloride (PVC Plastic). Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the solution container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g. di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million; however, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by cell culture toxicity studies. Structural Formula Dextrose Hydrous USP

10 OVERDOSAGE There is a potential for overdose resulting in hypervolemia, hypovolemia, electrolyte disturbances or hyperglycemia. Excessive use of DIANEAL peritoneal dialysis solution with 4.25% dextrose during a peritoneal dialysis treatment can result in significant removal of water from the patient.

How Supplied / Storage and Handling

openFDA Drug Labeling

16 HOW SUPPLIED/STORAGE AND HANDLING DIANEAL peritoneal dialysis solutions are available in the following single-dose containers and fill volumes as shown in Tables 6-7. The solution is clear with color being slightly yellow to colorless. Table 6 - DIANEAL Peritoneal Dialysis Solutions for CAPD therapy Container Fill Volume (mL) Container Size (mL) Product Code NDC ULTRABAG Container DIANEAL PD-2 Peritoneal Dialysis Solution with 1.5% Dextrose 2000 2500 2000 3000 5B9866 5B9868 0941-0426-52 0941-0426-53 DIANEAL PD-2 Peritoneal Dialysis Solution with 2.5% Dextrose 2000 2500 2000 3000 5B9876 5B9878 0941-0427-52 0941-0427-53 DIANEAL PD-2 Peritoneal Dialysis Solution with 4.25% Dextrose 2000 2500 2000 3000 5B9896 5B9898 0941-0429-52 0941-0429-53 DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose 1500 2000 2500 2000 2000 3000 5B9765 5B9766 5B9768 0941-0424-51 0941-0424-52 0941-0424-53 DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 1500 2000 2500 2000 2000 3000 5B9775 5B9776 5B9778 0941-0430-51 0941-0430-52 0941-0430-53 DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 4.25% Dextrose 1500 2000 2500 2000 2000 3000 5B9795 5B9796 5B9798 0941-0433-51 0941-0433-52 0941-0433-53 Table 7 - DIANEAL Peritoneal Dialysis Solutions for APD therapy Container Fill Volume (mL) Container Size (mL) Product Code NDC AMBU-FLEX / Plastic Container with pull ring DIANEAL PD-2 Peritoneal Dialysis Solution with 1.5% Dextrose 1000 2000 3000 5000 6000 1000 3000 3000 6000 6000 L5B5163 L5B5166 L5B5169 L5B5193 L5B9710 0941-0411-05 0941-0411-06 0941-0411-04 0941-0411-07 0941-0411-11 DIANEAL PD-2 Peritoneal Dialysis Solution with 2.5% Dextrose 1000 2000 3000 5000 6000 1000 3000 3000 6000 6000 L5B5173 L5B5177 L5B5179 L5B5194 L5B9711 0941-0413-05 0941-0413-06 0941-0413-04 0941-0413-07 0941-0413-01 DIANEAL PD-2 Peritoneal Dialysis Solution with 4.25% Dextrose 1000 2000 3000 5000 6000 1000 3000 3000 6000 6000 L5B5183 L5B5187 L5B5189 L5B5195 L5B9712 0941-0415-05 0941-0415-06 0941-0415-04 0941-0415-07 0941-0415-01 DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5%Dextrose 2000 3000 5000 6000 3000 3000 6000 6000 L5B4825 L5B9901 L5B4826 L5B9770 0941-0409-06 0941-0409-05 0941-0409-07 0941-0409-01 DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 2000 3000 5000 6000 3000 3000 6000 6000 L5B9727 L5B9902 L5B5202 L5B9771 0941-0457-08 0941-0457-02 0941-0457-05 0941-0457-01 DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 4.25% Dextrose 2000 3000 5000 6000 3000 3000 6000 6000 L5B9747 L5B9903 L5B5203 L5B9772 0941-0459-08 0941-0459-02 0941-0459-05 0941-0459-01 Plastic container with blue pull tip DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 1.5% Dextrose 5000 5000 EZPB5245R 0941-0484-01 DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000 5000 EZPB5255R 0941-0487-01 DIANEAL Low Calcium (2.5 mEq/L) Peritoneal Dialysis Solution with 4.25% Dextrose 5000 5000 EZPB5265R 0941-0490-01 All DIANEAL peritoneal dialysis solutions have overfills which are declared on container labeling. Freezing of solution may occur at temperatures below 0°C (32°F). Allow to thaw naturally in ambient conditions and thoroughly mix contents by shaking. Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C/77°F): brief exposure up to 40°C (104°F) does not adversely affect the product. Store in moisture barrier overwrap and in carton until ready to use.

Adverse event reports

Source: openFDA FAERS
271,787
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: SODIUM CHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II July 17, 2024 Baxter Healthcare Corporation Lack of Assurance of Sterility: Potential presence of leaks originating from the Connector Assembly component. Ongoing
Class II September 6, 2023 Baxter Healthcare Corporation Lack of Assurance of Sterility: Potential presence of leaks originating from the Luer component. Terminated
Class II September 6, 2023 Baxter Healthcare Corporation Lack of Assurance of Sterility: Potential presence of leaks originating from the Luer component. Terminated
Class II May 3, 2023 Baxter Healthcare Corporation Lack of Assurance of Sterility: Potential presence of leaks originating from the Luer component. Completed
Class II May 3, 2023 Baxter Healthcare Corporation Lack of Assurance of Sterility: Potential presence of leaks originating from the Luer component. Completed
Class II January 16, 2019 Baxter Healthcare Corporation Lack of Assurance of Sterility: Confirmed customer complaints for leaks on the tubing. Terminated
Class I October 8, 2014 Baxter Healthcare Corp. Presence of Particulate Matter: particulate matter was found during the manufacturing process. Terminated
Class I May 7, 2014 Baxter Healthcare Corp. Non-Sterility: Complaints of leaks and particulate matter identified as mold in the solution bag and the overpouch. Terminated
Class II August 7, 2013 Baxter Healthcare Corp. Defective Container: There is a potential for frangible components to be broken, resulting in a leak at the port when the closure is removed. Terminated

Shortages

Source: FDA Drug Shortages
Availability records from the FDA Drug Shortages database.
Status Availability Company Presentation Updated
To Be Discontinued Vantive US Healthcare LLC DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0459-05) August 3, 2026
To Be Discontinued Vantive US Healthcare LLC DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0433-51) August 3, 2026
To Be Discontinued Vantive US Healthcare LLC DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0424-51) August 3, 2026
To Be Discontinued Vantive US Healthcare LLC DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0457-05) August 3, 2026
To Be Discontinued Vantive US Healthcare LLC DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0409-07) August 3, 2026
To Be Discontinued Vantive US Healthcare LLC DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0430-51) August 3, 2026

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0941-0409-01 0941-0409 Vantive US Healthcare LLC 6000 mL in 1 BAG (0941-0409-01) September 27, 1978
0941-0409-05 0941-0409 Vantive US Healthcare LLC 3000 mL in 1 BAG (0941-0409-05) September 27, 1978
0941-0409-06 0941-0409 Vantive US Healthcare LLC 2000 mL in 1 BAG (0941-0409-06) September 27, 1978
0941-0409-07 0941-0409 Vantive US Healthcare LLC 5000 mL in 1 BAG (0941-0409-07) September 27, 1978
0941-0424-51 0941-0424 Vantive US Healthcare LLC 1500 mL in 1 BAG (0941-0424-51) December 4, 1992
0941-0424-52 0941-0424 Vantive US Healthcare LLC 2000 mL in 1 BAG (0941-0424-52) December 4, 1992
0941-0424-53 0941-0424 Vantive US Healthcare LLC 2500 mL in 1 BAG (0941-0424-53) December 4, 1992
0941-0430-51 0941-0430 Vantive US Healthcare LLC 1500 mL in 1 BAG (0941-0430-51) December 4, 1992
0941-0430-52 0941-0430 Vantive US Healthcare LLC 2000 mL in 1 BAG (0941-0430-52) December 4, 1992
0941-0430-53 0941-0430 Vantive US Healthcare LLC 2500 mL in 1 BAG (0941-0430-53) December 4, 1992
0941-0433-51 0941-0433 Vantive US Healthcare LLC 1500 mL in 1 BAG (0941-0433-51) December 4, 1992
0941-0433-52 0941-0433 Vantive US Healthcare LLC 2000 mL in 1 BAG (0941-0433-52) December 4, 1992
0941-0433-53 0941-0433 Vantive US Healthcare LLC 2500 mL in 1 BAG (0941-0433-53) December 4, 1992
0941-0457-01 0941-0457 Vantive US Healthcare LLC 6000 mL in 1 BAG (0941-0457-01) September 27, 1978
0941-0457-02 0941-0457 Vantive US Healthcare LLC 3000 mL in 1 BAG (0941-0457-02) September 27, 1978
0941-0457-05 0941-0457 Vantive US Healthcare LLC 5000 mL in 1 BAG (0941-0457-05) September 27, 1978
0941-0457-08 0941-0457 Vantive US Healthcare LLC 2000 mL in 1 BAG (0941-0457-08) September 27, 1978
0941-0459-01 0941-0459 Vantive US Healthcare LLC 6000 mL in 1 BAG (0941-0459-01) September 27, 1978
0941-0459-02 0941-0459 Vantive US Healthcare LLC 3000 mL in 1 BAG (0941-0459-02) September 27, 1978
0941-0459-05 0941-0459 Vantive US Healthcare LLC 5000 mL in 1 BAG (0941-0459-05) September 27, 1978
0941-0459-08 0941-0459 Vantive US Healthcare LLC 2000 mL in 1 BAG (0941-0459-08) September 27, 1978
0941-0484-01 0941-0484 Vantive US Healthcare LLC 5000 mL in 1 BAG (0941-0484-01) September 27, 1978
0941-0487-01 0941-0487 Vantive US Healthcare LLC 5000 mL in 1 BAG (0941-0487-01) September 27, 1978
0941-0490-01 0941-0490 Vantive US Healthcare LLC 5000 mL in 1 BAG (0941-0490-01) September 27, 1978
0941-0684-04 0941-0684 Vantive US Healthcare LLC 4 BAG in 1 CARTON (0941-0684-04) / 2500 mL in 1 BAG (0941-0684-01) November 1, 2024
0941-0686-08 0941-0686 Vantive US Healthcare LLC 8 BAG in 1 CARTON (0941-0686-08) / 2000 mL in 1 BAG (0941-0686-01) November 1, 2024
0941-0688-04 0941-0688 Vantive US Healthcare LLC 4 BAG in 1 CARTON (0941-0688-04) / 2500 mL in 1 BAG (0941-0688-01) November 1, 2024
0941-0690-08 0941-0690 Vantive US Healthcare LLC 8 BAG in 1 CARTON (0941-0690-08) / 2000 mL in 1 BAG (0941-0690-01) November 1, 2024
0941-0692-04 0941-0692 Vantive US Healthcare LLC 4 BAG in 1 CARTON (0941-0692-04) / 2500 mL in 1 BAG (0941-0692-01) November 1, 2024
0941-0694-08 0941-0694 Vantive US Healthcare LLC 8 BAG in 1 CARTON (0941-0694-08) / 2000 mL in 1 BAG (0941-0694-01) November 1, 2024
0941-0696-06 0941-0696 Vantive US Healthcare LLC 6 BAG in 1 CARTON (0941-0696-06) / 2000 mL in 1 BAG (0941-0696-01) October 30, 2024
0941-0701-02 0941-0701 Vantive US Healthcare LLC 2 BAG in 1 CARTON (0941-0701-02) / 6000 mL in 1 BAG (0941-0701-01) November 7, 2024
0941-0703-02 0941-0703 Vantive US Healthcare LLC 2 BAG in 1 CARTON (0941-0703-02) / 6000 mL in 1 BAG (0941-0703-01) November 7, 2024
0941-0705-02 0941-0705 Vantive US Healthcare LLC 2 BAG in 1 CARTON (0941-0705-02) / 5000 mL in 1 BAG (0941-0705-01) October 28, 2024
0941-0711-06 0941-0711 Vantive US Healthcare LLC 6 BAG in 1 CARTON (0941-0711-06) / 2000 mL in 1 BAG (0941-0711-01) October 23, 2024
0941-0713-06 0941-0713 Vantive US Healthcare LLC 6 BAG in 1 CARTON (0941-0713-06) / 2000 mL in 1 BAG (0941-0713-01) October 23, 2024
0941-0727-02 0941-0727 Vantive US Healthcare LLC 2 BAG in 1 CARTON (0941-0727-02) / 5000 mL in 1 BAG (0941-0727-01) October 29, 2024
0941-0729-02 0941-0729 Vantive US Healthcare LLC 2 BAG in 1 CARTON (0941-0729-02) / 5000 mL in 1 BAG (0941-0729-01) October 29, 2024
0941-0731-02 0941-0731 Vantive US Healthcare LLC 2 BAG in 1 CARTON (0941-0731-02) / 5000 mL in 1 BAG (0941-0731-01) October 29, 2024
0941-0733-04 0941-0733 Vantive US Healthcare LLC 4 BAG in 1 CARTON (0941-0733-04) / 2500 mL in 1 BAG (0941-0733-01) November 6, 2024
0941-0735-04 0941-0735 Vantive US Healthcare LLC 4 BAG in 1 CARTON (0941-0735-04) / 2500 mL in 1 BAG (0941-0735-01) November 6, 2024
0941-0409 0941-0409 Vantive US Healthcare LLC — September 27, 1978
0941-0424 0941-0424 Vantive US Healthcare LLC — December 4, 1992
0941-0430 0941-0430 Vantive US Healthcare LLC — December 4, 1992
0941-0433 0941-0433 Vantive US Healthcare LLC — December 4, 1992
0941-0457 0941-0457 Vantive US Healthcare LLC — September 27, 1978
0941-0459 0941-0459 Vantive US Healthcare LLC — September 27, 1978
0941-0484 0941-0484 Vantive US Healthcare LLC — September 27, 1978
0941-0487 0941-0487 Vantive US Healthcare LLC — September 27, 1978
0941-0490 0941-0490 Vantive US Healthcare LLC — September 27, 1978
0941-0684 0941-0684 Vantive US Healthcare LLC — November 1, 2024
0941-0686 0941-0686 Vantive US Healthcare LLC — November 1, 2024
0941-0688 0941-0688 Vantive US Healthcare LLC — November 1, 2024
0941-0690 0941-0690 Vantive US Healthcare LLC — November 1, 2024
0941-0692 0941-0692 Vantive US Healthcare LLC — November 1, 2024
0941-0694 0941-0694 Vantive US Healthcare LLC — November 1, 2024
0941-0696 0941-0696 Vantive US Healthcare LLC — October 30, 2024
0941-0701 0941-0701 Vantive US Healthcare LLC — November 7, 2024
0941-0703 0941-0703 Vantive US Healthcare LLC — November 7, 2024
0941-0705 0941-0705 Vantive US Healthcare LLC — October 28, 2024
0941-0711 0941-0711 Vantive US Healthcare LLC — October 23, 2024
0941-0713 0941-0713 Vantive US Healthcare LLC — October 23, 2024
0941-0727 0941-0727 Vantive US Healthcare LLC — October 29, 2024
0941-0729 0941-0729 Vantive US Healthcare LLC — October 29, 2024
0941-0731 0941-0731 Vantive US Healthcare LLC — October 29, 2024
0941-0733 0941-0733 Vantive US Healthcare LLC — November 6, 2024
0941-0735 0941-0735 Vantive US Healthcare LLC — November 6, 2024

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records
Drug Shortages FDA Supply availability

Generated September 25, 2026 · 13 sections on this page.